Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

Alterna extends its children's ElixSure line with spill-resistant formulations of ElixSure Liquid Allergy (diphenhydramine 12.5 mg) in bubble gum flavor and ElixSure EX Liquid Expectorant (guaifenesin 50 mg) in strawberry. The products come in 4 oz. bottles for $5.99 each, and will be available in early fall. The extensions add to the line's current formulations, which include Congestion (pseudoephedrine HCl), Cough (dextromethorphan HBr) and Fever/Pain. Alterna announced its acquisition of the ElixSure line from Taro Consumer in March (1"The Tan Sheet," March 7, 2005, p. 11)...

You may also be interested in...

Taro Readies Branded OTC Exodus With ElixSure, Kerasal Divestiture

Taro's divestiture of its ElixSure cough/cold medicine and Kerasal moisturizer brands in North America to Alterna signals the firm's exit from the branded OTC drug market

Dosing Guidance Lacking For Leading COVID-19 Antiviral Therapies, ASHP Analysis Shows

Health-system pharmacist organization assesses the evidence behind off-label use of existing drugs for COVID-19, along with top investigational prospects like Gilead’s remdesivir. 

Quality Should Ride Shotgun As US Auto Makers Rev Engine On Making Ventilators

As American auto giants GM and Ford take the wheel on working with ventilator manufacturers to make the critically needed devices during the COVID-19 pandemic, two longtime quality experts explain where the device and auto companies will find common ground when it comes to quality systems.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts